Relay Therapeutics (RLAY) Competitors $4.46 +0.14 (+3.24%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RLAY vs. ACAD, VCEL, XENE, MLTX, MOR, DNLI, SWTX, MRUS, ZLAB, and BHCShould you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include ACADIA Pharmaceuticals (ACAD), Vericel (VCEL), Xenon Pharmaceuticals (XENE), MoonLake Immunotherapeutics (MLTX), MorphoSys (MOR), Denali Therapeutics (DNLI), SpringWorks Therapeutics (SWTX), Merus (MRUS), Zai Lab (ZLAB), and Bausch Health Companies (BHC). These companies are all part of the "pharmaceutical products" industry. Relay Therapeutics vs. ACADIA Pharmaceuticals Vericel Xenon Pharmaceuticals MoonLake Immunotherapeutics MorphoSys Denali Therapeutics SpringWorks Therapeutics Merus Zai Lab Bausch Health Companies Relay Therapeutics (NASDAQ:RLAY) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, community ranking, media sentiment, risk, dividends and valuation. Which has preferable valuation and earnings, RLAY or ACAD? ACADIA Pharmaceuticals has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelay Therapeutics$10.01M74.61-$341.97M-$2.61-1.71ACADIA Pharmaceuticals$726.44M4.02-$61.29M$0.7822.53 Which has more risk & volatility, RLAY or ACAD? Relay Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Does the MarketBeat Community favor RLAY or ACAD? ACADIA Pharmaceuticals received 834 more outperform votes than Relay Therapeutics when rated by MarketBeat users. Likewise, 73.14% of users gave ACADIA Pharmaceuticals an outperform vote while only 69.41% of users gave Relay Therapeutics an outperform vote. CompanyUnderperformOutperformRelay TherapeuticsOutperform Votes5969.41% Underperform Votes2630.59% ACADIA PharmaceuticalsOutperform Votes89373.14% Underperform Votes32826.86% Do insiders & institutionals have more ownership in RLAY or ACAD? 97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 4.3% of Relay Therapeutics shares are owned by company insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts recommend RLAY or ACAD? Relay Therapeutics currently has a consensus target price of $20.50, indicating a potential upside of 359.64%. ACADIA Pharmaceuticals has a consensus target price of $25.25, indicating a potential upside of 43.71%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Relay Therapeutics is more favorable than ACADIA Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relay Therapeutics 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91ACADIA Pharmaceuticals 0 Sell rating(s) 7 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.59 Does the media refer more to RLAY or ACAD? In the previous week, Relay Therapeutics and Relay Therapeutics both had 14 articles in the media. ACADIA Pharmaceuticals' average media sentiment score of 0.73 beat Relay Therapeutics' score of 0.29 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is RLAY or ACAD more profitable? ACADIA Pharmaceuticals has a net margin of 13.83% compared to Relay Therapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Relay Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Relay TherapeuticsN/A -45.75% -40.75% ACADIA Pharmaceuticals 13.83%25.83%14.71% SummaryACADIA Pharmaceuticals beats Relay Therapeutics on 11 of the 16 factors compared between the two stocks. Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLAY vs. The Competition Export to ExcelMetricRelay TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$746.53M$2.96B$5.35B$9.06BDividend YieldN/A1.94%5.13%4.02%P/E Ratio-1.7145.5689.4817.34Price / Sales74.61358.881,251.39134.53Price / CashN/A192.9043.7535.97Price / Book0.763.975.324.80Net Income-$341.97M-$41.02M$122.60M$224.91M7 Day Performance0.22%8.62%0.88%1.90%1 Month Performance6.19%10.70%4.81%5.08%1 Year Performance-56.66%5.54%27.90%21.15% Relay Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLAYRelay Therapeutics2.3863 of 5 stars$4.46+3.2%$20.50+359.6%-57.2%$746.53M$10.01M-1.71330Analyst ForecastShort Interest ↑News CoverageACADACADIA Pharmaceuticals4.0028 of 5 stars$17.79+3.1%$25.25+41.9%-37.2%$2.96B$929.24M22.81510Short Interest ↑News CoverageVCELVericel1.7654 of 5 stars$59.89+0.7%$61.14+2.1%+56.1%$2.96B$226.84M998.33300Analyst ForecastAnalyst RevisionNews CoverageXENEXenon Pharmaceuticals2.7019 of 5 stars$38.24-0.4%$56.00+46.4%-15.6%$2.92B$9.43M-13.56210News CoveragePositive NewsMLTXMoonLake Immunotherapeutics1.9666 of 5 stars$45.44-1.9%$81.43+79.2%-22.3%$2.90BN/A-35.222Analyst UpgradeNews CoverageMORMorphoSys0.215 of 5 stars$18.96flat$14.33-24.4%N/A$2.86B$238.28M-5.45730DNLIDenali Therapeutics4.4114 of 5 stars$19.34+1.3%$38.91+101.2%+28.1%$2.78B$330.53M-7.01430Analyst ForecastShort Interest ↑SWTXSpringWorks Therapeutics1.6334 of 5 stars$37.31-13.2%$70.00+87.6%-13.8%$2.78B$135.49M-9.62230Analyst RevisionNews CoverageMRUSMerus2.9738 of 5 stars$40.49-7.7%$85.64+111.5%+22.7%$2.77B$35.93M-10.2537Short Interest ↓News CoverageHigh Trading VolumeZLABZai Lab2.4769 of 5 stars$25.07-0.9%$55.00+119.4%+11.2%$2.74B$355.75M-9.052,175News CoverageBHCBausch Health Companies3.3235 of 5 stars$7.47-5.2%$7.75+3.7%-8.9%$2.70B$9.47B-15.5620,270Short Interest ↓News CoveragePositive News Related Companies and Tools Related Companies ACAD Alternatives VCEL Alternatives XENE Alternatives MLTX Alternatives MOR Alternatives DNLI Alternatives SWTX Alternatives MRUS Alternatives ZLAB Alternatives BHC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RLAY) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
